AbstractWe investigated the association between SLC6A3 gene polymorphisms and changes in dopamine transporter (DAT) availability after glucose loading in humans. An intravenous injection of 18F‐FP‐CIT was administered after infusion of glucose or placebo, and the emission data were acquired over 90 min in 38 healthy male participants. DAT availability expressed in terms of binding potential (BPND) was recorded. The 40‐bp variable number of tandem repeats (VNTR) in the 3′ untranslated region and two single nucleotide polymorphisms (SNPs), rs2652511 and rs2937639, in the SLC6A3 gene were genotyped. Among the 38 participants, those with a VNTR other than 10R/10R (n = 7) were excluded. The alleles of the two SNPs (rs2652511 and rs2937639) appeared to be inherited together in two fixed combinations (C–G or T–A) in 29 of 31 individuals. The BPND in the ventral striatum (VST), caudate nucleus, and putamen was not significantly different after glucose or placebo loading according to genotype. However, BPNDs from the caudate nucleus and putamen of all participants with rs2652511 CT/rs2937639 AG (n = 6) were higher after glucose loading. In conclusion, the SLC6A3 gene polymorphism is associated with the changes in DAT availability after glucose loading. DAT availability after glucose or placebo loading in the VST, caudate nucleus, and putamen did not differ according to the SLC6A3 genotype.

2020-09-01·Annals of Clinical and Translational Neurology2区 · 医学

Imaging of dopamine transporters in Parkinson disease: a meta‐analysis of ¹⁸F/¹²³I‐FP‐CIT studies

2区 · 医学

ArticleOA

作者: Wagle Shukla, Aparna ; Zhang, Chencheng ; Liu, Kawai ; Kong, Yanyan ; Guan, Yihui ; Sun, Bomin

AbstractObjective18F‐FP‐CIT and 123I‐FP‐CIT are widely used radiotracers in molecular imaging for Parkinson’s disease (PD) diagnosis. Compared with 123I‐FP‐CIT, 18F‐FP‐CIT has superior tracer kinetics. We aimed to conduct a meta‐analysis to assess the efficacy of using 18F‐FP‐CIT positron emission tomography (PET) and 123I‐FP‐CIT single‐photon emission computed tomography (SPECT) of dopamine transporters in patients with PD in order to provide evidence for clinical decision‐making.MethodsWe searched the PubMed, Embase, Wanfang Data, and China National Knowledge Infrastructure databases to identify the relevant studies from the time of inception of the databases to 30 April 2020. We identified six PET studies, including 779 patients with PD and 124 healthy controls, which met the inclusion criteria. Twenty‐seven SPECT studies with 1244 PD patients and 859 controls were also included in this meta‐analysis.ResultsOverall effect‐size analysis indicated that patients with PD showed significantly reduced 18F‐FP‐CIT uptake in three brain regions [caudate nucleus: standardized mean difference (SMD) = −1.71, Z = −3.31, P = 0.0009; anterior putamen: SMD = −3.71, Z = −6.26, P < 0.0001; and posterior putamen: SMD = −5.49, Z = −5.97, P < 0.0001]. Significant decreases of 123I‐FP‐CIT uptake were also observed in the caudate (SMD = −2.31, Z = −11.49, P < 0.0001) and putamen (SMD = −3.25, Z = −14.79, P < 0.0001).InterpretationIn conclusion, our findings indicate that both 18F‐FP‐CIT PET and 123I‐FP‐CIT SPECT imaging of dopamine transporters can provide viable biomarkers for early PD diagnosis.

2020-01-01·Diabetes, Obesity and Metabolism

Striatal dopamine transporter changes after glucose loading in humans

Article

作者: Im, Hyung‐Jun ; Kim, Seong‐Jang ; Kim, Keunyoung ; Seo, Seongho ; Lee, Myung Jun ; Park, Jung‐Jun ; Pak, Kyoungjune ; Shin, Myung Jun ; Suh, Sunghwan ; Kim, In Joo

AbstractAimsThe dopamine transporter (DAT) actively translocates dopamine that is released from the presynaptic neurons across the membranes of nerve terminals into the extracellular space. We hypothesized that glucose loading‐induced changes in striatal DAT levels could be associated with food intake in humans.Materials and methodsAn intravenous bolus injection of 18F‐FP‐CIT was administered after infusion of glucose or placebo (normal saline), and emission data were acquired over 90 minutes in 33 healthy males. For a volume‐of‐interest‐based analysis, an atlas involving sub‐striatal regions of ventral striatum (VST), caudate nucleus and putamen was applied. DAT availability and binding potential (BPND) were measured using a simplified reference tissue method with cerebellum as the reference.ResultsThe glucose‐loaded BPND from the VST negatively correlated with body mass index (BMI), whereas the placebo‐loaded BPND from the VST did not. After loading with glucose, there were substantial increases in BPNDs: 18.3%, 71.7% and 34.0% on average in the VST, caudate nucleus and putamen, respectively.ConclusionStriatal DAT changes after glucose loading, and BMI is associated with glucose‐loaded DAT availability, not with placebo‐loaded DAT availability. DAT might have a role in the reward system of eating behavior.

100 项与 18F-FP-CIT 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	V09	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
帕金森病	韩国	FutureChem Co., Ltd.	2008-05-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特发性震颤	药物发现	-	Zionexa SAS	2020-05-01
帕金森病	药物发现	-	Zionexa SAS	2020-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


MDS2022	N/A	帕金森病	227	18F-FP-CIT PET	蓋構顧遞鑰膚鑰壓顧壓(艱鹹鑰夢廠襯遞襯鏇醖): hazard ratio = 2.743 (95% CI, 1.371 ~ 5.486), P-Value = 0.004	-	2022-09-15
				18F-FP-CIT PET